EGFR and lung carcinoma: In the study of Patel et al. [214], it was proposed a design of polymer nanoparticle-antibody complex consisting of poly(lactide-co-glycolide) (PLGA) nanoparticles conjugated with anti-EGFR (epidermal growth factor receptor) antibodies that target the lung cancer cells.